http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017514801-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C237-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-50 |
| filingDate | 2015-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017514801-A |
| titleOfInvention | Double acylated GLP-1 compound |
| abstract | The present invention is a derivative of GLP-1 peptide, wherein the peptide is located at the position corresponding to position 36 of GLP-1 (7-37) (SEQ ID NO: 1), the first Lys residue, GLP-1 (7- 37) a derivative containing a second Lys residue at a position corresponding to position 37 of (SEQ ID NO: 1) and up to 7 amino acid changes compared to GLP-1 (7-37) (SEQ ID NO: 1) Each of the first and second Lys residues, each comprising two extension parts bonded via a linker, the extension part is Chem. 1: HOOC-C 6 H 4 -O- (CH 2 ) y -CO- * and Chem. 2 : HOOC (CH 2 ) x -CO- *, wherein y is an integer in the range 8-11, x is 12, and the linker is Chem .3: * -NH-CH (COOH)-(CH 2 ) 2 -CO- *, Chem. 4: * -NH-CH ((CH 2 ) 2 -COOH) -CO- *, and / or Chem. 5: * Includes at least one of NH- (CH 2 ) 2- [O- (CH 2 ) 2 ] k -O- [CH 2 ] n -CO- *, wherein k is in the range of 1 to 5 A derivative wherein n is an integer ranging from 1 to 5, or a pharmaceutically acceptable salt, amide or Regarding esters. The present invention also forms part of these pharmaceutical uses, such as for the treatment of diabetes and obesity, and derivatives thereof having Lys residues at positions 36 and 37 and no other Lys residues. GLP-1 peptides as well as these GLP-1 (9-37) fragments. The invention further relates to an intermediate product comprising 3-carboxyphenoxy-nonanoic acid having a protecting group on the carboxy group of nonanoic acid, optionally via a linker. The derivatives have very good potency and long half-life, which makes them potentially useful for oral administration, for example. |
| priorityDate | 2014-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 441.